ADVFN Logo
Boards:
    Quotes:
      Boards
      News
      Market Data
      Markets
      Discover
      Subscribe Login/Register Profile Icon
      S&P 500
      5,584.62
      -0.87%
      US Tech 100
      19,644.74
      -2.35%
      Dow Jones
      39,772.46
      0.13%
      Brent Oil
      84.94
      -0.13%
      Bitcoin
      57,886.19
      0.23%
      Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
      Get Started
      1. Home
      2. Investing
      3. Stocks
      4. Europe
      5. EU
      6. Sanofi (SAN)

      7. Sanofi (SAN) News

      SAN

      Sanofi (SAN)

      Sanofi
      		Date:
      Sort by:
       Showing the most relevant articles for your search:EU:SAN
      DateTimeSourceHeadlineSymbolCompany
      12:21PMiHub NewswireFeaturedCannabix Technologies and Omega Laboratories Inc. Provide Positive Developments on Marijuana Breathalyzer Testing
      09/26/20231:30AMGlobeNewswire Inc.Press Release: Dupixent® (dupilumab) sBLA for treatment of eosinophilic esophagitis in children aged 1 to 11 accepted for FDA Priority ReviewEU:SANSanofi
      09/26/20231:30AMGlobeNewswire Inc.Press Release: Dupixent® (dupilumab) sBLA for treatment of eosinophilic esophagitis in children aged 1 to 11 accepted for FDA Priority ReviewEU:SANSanofi
      09/26/20231:30AMGlobeNewswire Inc.Communiqué de presse : La FDA accorde un examen prioritaire à Dupixent® (dupilumab) pour le traitement de l’œsophagite à éosinophiles de l’enfant âgé de 1 à 11 ansEU:SANSanofi
      09/26/20231:29AMGlobeNewswire Inc.Dupixent® (dupilumab) sBLA for Treatment of Eosinophilic Esophagitis (EoE) in Children Aged 1 to 11 Accepted for FDA Priority ReviewEU:SANSanofi
      09/25/20233:37AMDow Jones NewsSanofi autorisé à commercialiser Altuviiio au Japon pour traiter l'hémophilie AEU:SANSanofi
      09/25/20233:32AMDow Jones NewsSanofi autorisé à commercialiser Altuviiio au Japon pour traiter l'hémophilie AEU:SANSanofi
      09/25/20233:00AMGlobeNewswire Inc.Press Release: Once-weekly ALTUVIIIO® approved in Japan as a new class of factor VIII therapy for hemophilia AEU:SANSanofi
      09/25/20233:00AMGlobeNewswire Inc.Communiqué de presse : ALTUVIIIO® une fois par semaine, une nouvelle classe de facteur VIII de remplacement, approuvé au Japon pour le traitement de l’hémophilie AEU:SANSanofi
      09/25/20233:00AMGlobeNewswire Inc.Press Release: Once-weekly ALTUVIIIO® approved in Japan as a new class of factor VIII therapy for hemophilia AEU:SANSanofi
      09/22/20232:45AMDow Jones NewsSanofi Expects Currency Hit to Sales, EarningsEU:SANSanofi
      09/22/20231:30AMGlobeNewswire Inc.Communiqué de presse : Mise en ligne du document « Q3 2023 Memorandum for modelling purposes »EU:SANSanofi
      09/22/20231:30AMGlobeNewswire Inc.Press Release: Availability of the Q3 2023 Memorandum for modelling purposesEU:SANSanofi
      09/19/20232:30AMGlobeNewswire Inc.Press Release: Sanofi supporting vulnerable communities as part of commitment to social impact and fight against climate changeEU:SANSanofi
      09/19/20232:30AMGlobeNewswire Inc.Press Release: Sanofi supporting vulnerable communities as part of commitment to social impact and fight against climate changeEU:SANSanofi
      09/19/20232:30AMGlobeNewswire Inc.Communiqué de presse : Sanofi soutient les communautés vulnérables dans le cadre de son engagement en faveur de l’impact social et de la lutte contre le changement climatiqueEU:SANSanofi
      09/14/20237:34AMDow Jones NewsFirst Wave BioPharma Shares Surge 82% on License Agreement with SanofiEU:SANSanofi
      09/11/20232:02PMGlobeNewswire Inc.Sanofi: Information concerning the total number of voting rights and shares - August 2023EU:SANSanofi
      09/11/20232:02PMGlobeNewswire Inc.Sanofi: Informations relatives au nombre de droits de vote et d'actions AOUT 2023EU:SANSanofi
      09/05/20234:36AMDow Jones NewsECHO BOURSE: Sanofi relevé de "conserver" à "acheter" par BerenbergEU:SANSanofi
      08/31/20233:58AMDow Jones NewsSanofi annonce le départ du patron de la médecine de spécialités, sa principale brancheEU:SANSanofi
      08/31/20233:53AMDow Jones NewsSanofi annonce le départ du patron de la médecine de spécialités, sa principale brancheEU:SANSanofi
      08/31/20231:30AMGlobeNewswire Inc.Press Release: Sanofi announces changes to its Executive CommitteeEU:SANSanofi
      08/31/20231:30AMGlobeNewswire Inc.Communiqué de presse: Sanofi annonce des changements au sein de son Comité exécutifEU:SANSanofi
      08/22/20232:16AMDow Jones NewsPfizer obtient l'aval de la FDA pour un vaccin maternel contre le VRSEU:SANSanofi
      08/22/20232:11AMDow Jones NewsPfizer obtient l'aval de la FDA pour un vaccin maternel contre le VRSEU:SANSanofi
      08/15/20233:24PMGlobeNewswire Inc.Sanofi: Informations relatives au nombre de droits de vote et d'actions - Juillet 2023EU:SANSanofi
      08/15/20233:24PMGlobeNewswire Inc.Sanofi: Information concerning the total number of voting rights and shares - July 2023EU:SANSanofi
      08/04/20233:17AMDow Jones NewsSanofi, AstraZeneca RSV Treatment for Infants Gets U.S. CDC Panel RecommendationEU:SANSanofi
      08/04/20231:41AMDow Jones NewsSanofi: le Beyfortus recommandé aux Etats-Unis contre le VRS chez les nourrissonsEU:SANSanofi
       Showing the most relevant articles for your search:EU:SAN